bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas
Authors: Corso Simona , Pietrantonio Filippo , Apicella Maria , Migliore Cristina , Conticelli Daniela , Petrelli Annalisa , D'Errico Laura , Durando Stefania , Moya-Rull Daniel , Bellomo Sara E. , Ughetto Stefano , Degiuli Maurizio , Reddavid Rossella , Fumagalli Uberto , De Pascale Stefano , Sgroi Giovanni , Rausa Emanuele , Baiocchi Gian Luca , Molfino Sarah , De Manzoni Giovanni , Bencivenga Maria , Siena Salvatore , Sartore-Bianchi Andrea , Morano Federica , Corallo Salvatore , Prisciandaro Michele , Di Bartolomeo Maria , Gloghini Annunziata , Marsoni Silvia , Sottile Antonino , Sapino Anna , Marchiò Caterina , Dahle-Smith Asa , Miedzybrodzka Zosia , Lee Jessica , Ali Siraj M. , Ross Jeffrey S. , Alexander Brian M. , Miller Vincent A. , Petty Russell , Schrock Alexa B. , Giordano Silvia
Published: April 2023

Supplementary Figure 1
Supplementary Figure S5 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S5 provides an overview of per patient ctDNA fraction and sequential treatment response (best prostate-specific antigen (PSA) decline and duration of response).
Supplementary Figure S22 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S22 shows treatment-associated changes in androgen receptor (AR) ligand binding domain mutations
Supplementary Figure 4 from FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC
Authors: Bickett Thomas E. , Knitz Michael , Darragh Laurel B. , Bhatia Shilpa , Van Court Benjamin , Gadwa Jacob , Bhuvane Shiv , Piper Miles , Nguyen Diemmy , Tu Hua , Lenz Laurel , Clambey Eric T. , Barry Kevin , Karam Sana D.
Published: April 2023

Supplementary Figure 4 (A) Gating strategy used in flow cytometry analysis analyzing NK46+ CD3-NK cells, CD11c+ MHCII+ DCs, CD3+ CD4+ T cells, and CD3+ CD8+ T cells. (B) Flow cytometry analysis of NK cell populations in blood from WT C57BL/6 mice treated with RT, anti-CD25, and anti-CD137; n=4. (C) Flow cytometry of CD4 T cell populations in tumors from WT C57BL/6 mice treated with RT, anti-CD25, and anti-CD137 and from DEREG mice treated with RT, anti-CD25, antiCD137, and diphtheria toxin (DT); *p{less than or equal to}0.05, ** p{less than or equal to}0.01; n=6. (D) FLT3L present in serum of C57BL6 treated with radiation therapy, anti-CD25, and anti-CD137, and DEREG mice treated with radiation therapy, anti-CD25, anti-CD137, and diphtheria toxin (DT); ** p{less than or equal to}0.01; n=6
Supplementary Figure S14 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S14 shows temporal changes in whole exome somatic mutation profiles in patients that had evidence for somatic mutation profile change based on 72-gene targeted sequencing.
Supplementary Figure S10 from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Authors: Annala Matti , Taavitsainen Sinja , Khalaf Daniel J. , Vandekerkhove Gillian , Beja Kevin , Sipola Joonatan , Warner Evan W. , Herberts Cameron , Wong Amanda , Fu Simon , Finch Daygen L. , Oja Conrad D. , Vergidis Joanna , Zulfiqar Muhammad , Eigl Bernhard J. , Kollmansberger Christian K. , Nykter Matti , Gleave Martin E. , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure S10 provides Kaplan-Meier plots showing duration of treatment response in patients with different baseline circulating tumor DNA fractions
Supplementary Table-S7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

Supplementary Table-S7
Supplementary Fig. 13 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

ESCC prediction accuracy using various number of DMRs identified from ESCC vs. healthy plasma sample analysis
Supplementary Fig. 12 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Authors: Kandimalla Raju , Xu Jianfeng , Link Alexander , Matsuyama Takatoshi , Yamamura Kensuke , Parker M. Iqbal , Uetake Hiroyuki , Balaguer Francesc , Borazanci Erkut , Tsai Susan , Evans Douglas , Meltzer Stephen J. , Baba Hideo , Brand Randall , Von Hoff Daniel , Li Wei , Goel Ajay
Published: April 2023

HCC prediction accuracy using various number of DMRs identified from HCC vs. healthy plasma sample analysis
Supplementary figure 8 from Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells
Authors: Rijnders Maud , Balcioglu Hayri E. , Robbrecht Debbie G.J. , Oostvogels Astrid A.M. , Wijers Rebecca , Aarts Maureen J.B. , Hamberg Paul , van Leenders Geert J.L.H. , Nakauma-González J. Alberto , Voortman Jens , Westgeest Hans M. , Boormans Joost L. , de Wit Ronald , Lolkema Martijn P. , van der Veldt Astrid A.M. , Debets Reno
Published: April 2023

Highlighted immune parameters in blood, plasma and tumor tissue from mUC patients with stable disease as best overall response to anti-PD1
Supplementary Data from Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Authors: Schwartz Christopher J. , da Silva Edaise M. , Marra Antonio , Gazzo Andrea M. , Selenica Pier , Rai Vikas K. , Mandelker Diana , Pareja Fresia , Misyura Maksym , D'Alfonso Timothy M. , Brogi Edi , Drullinsky Pamela , Razavi Pedram , Robson Mark E. , Drago Joshua Z. , Wen Hannah Y. , Zhang Liying , Weigelt Britta , Shia Jinru , Reis-Filho Jorge S. , Zhang Hong
Published: April 2023

Supplementary Figure 1. Comparison of tumor mutational burden, dominant mutational signatures and MSISensor scores of Lynch syndrome BC cohort to control-matched BC cohort using MSK-IMPACT targeted sequencing.
Table S2 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Authors: Sinn Bruno V. , Loibl Sibylle , Hanusch Claus A. , Zahm Dirk-Michael , Sinn Hans-Peter , Untch Michael , Weber Karsten , Karn Thomas , Becker Clemens , Marmé Frederik , Schmitt Wolfgang D. , Müller Volkmar , Schem Christian , Treue Denise , Stickeler Elmar , Klauschen Frederik , Burchardi Nicole , Furlanetto Jenny , van Mackelenbergh Marion , Fasching Peter A. , Schneeweiss Andreas , Denkert Carsten
Published: April 2023

Differentially expressed genes according to treatment response
Figure S3 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Authors: Sinn Bruno V. , Loibl Sibylle , Hanusch Claus A. , Zahm Dirk-Michael , Sinn Hans-Peter , Untch Michael , Weber Karsten , Karn Thomas , Becker Clemens , Marmé Frederik , Schmitt Wolfgang D. , Müller Volkmar , Schem Christian , Treue Denise , Stickeler Elmar , Klauschen Frederik , Burchardi Nicole , Furlanetto Jenny , van Mackelenbergh Marion , Fasching Peter A. , Schneeweiss Andreas , Denkert Carsten
Published: April 2023

(A) Paired scatter plot demonstrating the correlation between the immune-associated gene expression and PD-L1. (B) PD-L1 immunohistochemistry and mRNA expression in pre-treatment core biopsies. The definition of >= 1 % of positively stained tumor cells is associated with CD274 (=PD-L1) mRNA expression (t-test P-value and area under the curve).
Supplemental Figure 1 from Whole-body PET Imaging of T-cell Response to Glioblastoma
Authors: Nobashi Tomomi W. , Mayer Aaron T. , Xiao Zunyu , Chan Carmel T. , Chaney Aisling M. , James Michelle L. , Gambhir Sanjiv S.
Published: April 2023

Supplemental Fig. S1. 89Zr-DFO-OX40 mAb PET in different time points post vaccination. (A) To explore the optimal timing to perform 89Zr-DFO-OX40 mAb PET post vaccination, early time point PET studies were conducted (The schedule in the main manuscript was described as late time point here, in which PET imaging was performed on day 3 post vaccination/day 1 post tracer injection). 89Zr-DFO-OX40 mAb was injected on the following day of vaccine treatment, and PET scanning was performed on day 1, 2, and 4. (B) Representative images of vaccinated and control mice in early and late time point imaging. Lymphatic organs were not visualized in both vaccinated and control groups in early time point imaging. (C) No significant difference in 89Zr-DFO-OX40 mAb uptake was seen through day 4 between vaccinated and control groups. Ax, axillary lymph node; Cer, cervical lymph node. Data are shown with mean {plus minus} SEM.
Supplementary Figures from Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers
Authors: Harms Kelly L. , Zhao Lili , Johnson Bryan , Wang Xiaoming , Carskadon Shannon , Palanisamy Nallasivam , Rhodes Daniel R. , Mannan Rahul , Vo Josh N. , Choi Jae Eun , Chan May P. , Fullen Douglas R. , Patel Rajiv M. , Siddiqui Javed , Ma Vincent T. , Hrycaj Steven , McLean Scott A. , Hughes Tasha M. , Bichakjian Christopher K. , Tomlins Scott A. , Harms Paul W.
Published: April 2023

Supplementary Figures S1-S4
Supplementary Figures from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Authors: Loehr Andrea , Patnaik Akash , Campbell David , Shapiro Jeremy , Bryce Alan H. , McDermott Ray , Sautois Brieuc , Vogelzang Nicholas J. , Bambury Richard M. , Voog Eric , Zhang Jingsong , Piulats Josep M. , Hussain Arif , Ryan Charles J. , Merseburger Axel S. , Daugaard Gedske , Heidenreich Axel , Fizazi Karim , Higano Celestia S. , Krieger Laurence E. , Sternberg Cora N. , Watkins Simon P. , Despain Darrin , Simmons Andrew D. , Dowson Melanie , Golsorkhi Tony , Chowdhury Simon , Abida Wassim
Published: April 2023

Supplementary Figure 1 and 2
Figure S8 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.
Figure S10 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.
Supplementary Table from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Authors: Wang Xian , Veeraraghavan Jamunarani , Liu Chia-Chia , Cao Xixi , Qin Lanfang , Kim Jin-Ah , Tan Ying , Loo Suet Kee , Hu Yiheng , Lin Ling , Lee Sanghoon , Shea Martin J. , Mitchell Tamika , Li Shunqiang , Ellis Matthew J. , Hilsenbeck Susan G. , Schiff Rachel , Wang Xiao-Song
Published: April 2023

Supplementary Tables
Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Authors: Lee Jung-Min , Moore Richard G. , Ghamande Sharad , Park Min S. , Diaz John P. , Chapman Julia , Kendrick James , Slomovitz Brian M. , Tewari Krishnansu S. , Lowe Elizabeth S. , Milenkova Tsveta , Kumar Sanjeev , Dymond Mike , Brown Jessica , Liu Joyce F.
Published: April 2023

Supplementary Data from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Table S2 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

List of differentially expressed proteins between Group 3 and Group 4 medulloblastoma in the Archer (3) and Forget (4) datasets.
Supplementary methods from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Supplementary methods
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplemental Appendix 5. Acute toxicity related to chemotherapy and chemoradiation.
Supplementary Table 5 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Authors: Nguyen Cong Trung , Caruso Stefano , Maille Pascale , Beaufrère Aurélie , Augustin Jérémy , Favre Loetitia , Pujals Anaïs , Boulagnon-Rombi Camille , Rhaiem Rami , Amaddeo Giuliana , di Tommaso Luca , Luciani Alain , Regnault Hélène , Brustia Raffaele , Scatton Olivier , Charlotte Frédéric , Brochériou Isabelle , Sommacale Daniele , Soussan Patrick , Leroy Vincent , Laurent Alexis , Le Van Ky , Ta Van To , Trinh Hong Son , Tran Thi Lan , Gentien David , Rapinat Audrey , Nault Jean Charles , Allaire Manon , Mulé Sebastien , Zucman-Rossi Jessica , Pawlotsky Jean-Michel , Tournigand Christophe , Lafdil Fouad , Paradis Valérie , Calderaro Julien
Published: April 2023

Supplementary Table 5: Difference in gene expression between Immune High (IH) and Immune Low (IL) subgroups from the validation dataset (n=20, Coulouarn et al, Carcinogenesis, 2012) (33).
Supplementary Table 2 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Authors: Nguyen Cong Trung , Caruso Stefano , Maille Pascale , Beaufrère Aurélie , Augustin Jérémy , Favre Loetitia , Pujals Anaïs , Boulagnon-Rombi Camille , Rhaiem Rami , Amaddeo Giuliana , di Tommaso Luca , Luciani Alain , Regnault Hélène , Brustia Raffaele , Scatton Olivier , Charlotte Frédéric , Brochériou Isabelle , Sommacale Daniele , Soussan Patrick , Leroy Vincent , Laurent Alexis , Le Van Ky , Ta Van To , Trinh Hong Son , Tran Thi Lan , Gentien David , Rapinat Audrey , Nault Jean Charles , Allaire Manon , Mulé Sebastien , Zucman-Rossi Jessica , Pawlotsky Jean-Michel , Tournigand Christophe , Lafdil Fouad , Paradis Valérie , Calderaro Julien
Published: April 2023

Supplementary Table 2: Immune subgroups and clinical, biological, and pathological features of the patients and tumors.
Supplementary Table 1 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
Authors: Nguyen Cong Trung , Caruso Stefano , Maille Pascale , Beaufrère Aurélie , Augustin Jérémy , Favre Loetitia , Pujals Anaïs , Boulagnon-Rombi Camille , Rhaiem Rami , Amaddeo Giuliana , di Tommaso Luca , Luciani Alain , Regnault Hélène , Brustia Raffaele , Scatton Olivier , Charlotte Frédéric , Brochériou Isabelle , Sommacale Daniele , Soussan Patrick , Leroy Vincent , Laurent Alexis , Le Van Ky , Ta Van To , Trinh Hong Son , Tran Thi Lan , Gentien David , Rapinat Audrey , Nault Jean Charles , Allaire Manon , Mulé Sebastien , Zucman-Rossi Jessica , Pawlotsky Jean-Michel , Tournigand Christophe , Lafdil Fouad , Paradis Valérie , Calderaro Julien
Published: April 2023

Supplementary Table 1: Difference in gene expression between IL and IH subtypes
Supplementary Figure S5 from Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition
Authors: Zhang Pu , Brinton Lindsey T. , Williams Katie , Sher Steven , Orwick Shelley , Tzung-Huei Lai , Mims Alice S. , Coss Christopher C. , Kulp Samuel K. , Youssef Youssef , Chan Wing Keung , Mitchell Shaneice , Mustonen Allison , Cannon Matthew , Phillips Hannah , Lehman Amy M. , Kauffman Tierney , Beaver Larry , Canfield Daniel , Grieselhuber Nicole R. , Alinari Lapo , Sampath Deepa , Yan Pearlly , Byrd John C. , Blachly James S. , Lapalombella Rosa
Published: April 2023

Combinations of AR-42 and KPT-9274 have no overlapping toxicities in vivo.
Supplementary Table from Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Wise-Draper Trisha M. , Gulati Shuchi , Palackdharry Sarah , Hinrichs Benjamin H. , Worden Francis P. , Old Matthew O. , Dunlap Neal E. , Kaczmar John M. , Patil Yash , Riaz Muhammed Kashif , Tang Alice , Mark Jonathan , Zender Chad , Gillenwater Ann M. , Bell Diana , Kurtzweil Nicky , Mathews Maria , Allen Casey L. , Mierzwa Michelle L. , Casper Keith , Jandarov Roman , Medvedovic Mario , Lee J. Jack , Harun Nusrat , Takiar Vinita , Gillison Maura
Published: April 2023

Supplementary Table from Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Supplementary Table from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Authors: Patel Krina K. , Shah Jatin J. , Feng Lei , Lee Hans C. , Manasanch Elisabet M. , Olsem Jasper , Morphey Ashley , Huo Xiao Jiao , Thomas Sheeba K. , Bashir Qaiser , Qazilbash Muzaffar H. , Weber Donna M. , Orlowski Robert Z.
Published: April 2023

Supplementary Table from Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
Supplementary Figure from Targeting Podoplanin for the Treatment of Osteosarcoma
Authors: Takemoto Ai , Takagi Satoshi , Ukaji Takao , Gyobu Nobuhiko , Kakino Mamoru , Takami Miho , Kobayashi Asami , Lebel Marie , Kawaguchi Tokuichi , Sugawara Minoru , Tsuji-Takayama Kazue , Ichihara Kenji , Funauchi Yuki , Ae Keisuke , Matsumoto Seiichi , Sugiura Yoshiya , Takeuchi Kengo , Noda Tetsuo , Katayama Ryohei , Fujita Naoya
Published: April 2023

Supplementary Figure from Targeting Podoplanin for the Treatment of Osteosarcoma
Supplementary Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Authors: Li Fuyang , Bondra Kathryn M. , Ghilu Samson , Studebaker Adam , Liu Qianqian , Michalek Joel E. , Kogiso Mari , Li Xiao-Nan , Kalapurakal John A. , James C. David , Burma Sandeep , Kurmasheva Raushan T. , Houghton Peter J.
Published: April 2023

Supplementary Data from Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models
Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Authors: Chen Li , Jiang Yi-Zhou , Wu Song-Yang , Wu Jiong , Di Gen-Hong , Liu Guang-Yu , Yu Ke-Da , Fan Lei , Li Jun-Jie , Hou Yi-Feng , Hu Zhen , Chen Can-Ming , Huang Xiao-Yan , Cao A-Yong , Hu Xin , Zhao Shen , Ma Xiao-Yan , Xu Ying , Sun Xiang-Jie , Chai Wen-Jun , Guo Xiaomao , Chen Xizi , Xu Yanhui , Zhu Xiao-Yu , Zou Jian-Jun , Yang Wen-Tao , Wang Zhong-Hua , Shao Zhi-Ming
Published: April 2023

Supplementary Table from Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Supplementary Data from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Authors: Yurchenko Andrey A. , Pop Oltin T. , Ighilahriz Meriem , Padioleau Ismael , Rajabi Fatemeh , Sharpe Hayley J. , Poulalhon Nicolas , Dreno Brigitte , Khammari Amir , Delord Marc , Alberti Antonio , Soufir Nadem , Battistella Maxime , Mourah Samia , Bouquet Fanny , Savina Ariel , Besse Andrej , Mendez-Lopez Max , Grange Florent , Monestier Sandrine , Mortier Laurent , Meyer Nicolas , Dutriaux Caroline , Robert Caroline , Saiag Philippe , Herms Florian , Lambert Jerome , de Sauvage Frederic J. , Dumaz Nicolas , Flatz Lukas , Basset-Seguin Nicole , Nikolaev Sergey I.
Published: April 2023

Supplementary Data from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
Supplementary Data from Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies
Authors: Collins Grace , Stewart Mark , McKelvey Brittany , Stires Hillary , Allen Jeff
Published: April 2023

Supplementary Data from Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies
Supplementary Figure S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Pharmacodynamic response to trametinib/ganitumab in xenograft models does not predict tumor shrinkage
Supplemental Table 1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Authors: Wainberg Zev A. , Singh Arun S. , Konecny Gottfried E. , McCann Kelly E. , Hecht J. Randolph , Goldman Jonathan , Chmielowski Bartosz , Finn Richard S. , O'Brien Neil , Von Euw Erika , Price Megan M. , Martinez Diego , Yonemoto Lisa , Brennan Meghan , Glaspy John A. , Slamon Dennis J.
Published: April 2023

Supplemental Table 1
Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Authors: Hebron Katie E. , Wan Xiaolin , Roth Jacob S. , Liewehr David J. , Sealover Nancy E. , Frye William J.E. , Kim Angela , Stauffer Stacey , Perkins Olivia L. , Sun Wenyue , Isanogle Kristine A. , Robinson Christina M. , James Amy , Awasthi Parirokh , Shankarappa Priya , Luo Xiaoling , Lei Haiyan , Butcher Donna , Smith Roberta , Edmondson Elijah F. , Chen Jin-Qiu , Kedei Noemi , Peer Cody J. , Shern Jack F. , Figg W. Douglas , Chen Lu , Hall Matthew D. , Difilippantonio Simone , Barr Frederic G. , Kortum Robert L. , Robey Robert W. , Vaseva Angelina V. , Khan Javed , Yohe Marielle E.
Published: April 2023

Related to Figure 3
Supplementary Data from OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Authors: Xu Zhenhua , Murad Najiba , Malawsky Daniel , Tao Ran , Rivero-Hinojosa Samuel , Holdhof Dörthe , Schüller Ulrich , Zhang Peng , Lazarski Christopher , Rood Brian R. , Packer Roger , Gershon Timothy , Pei Yanxin
Published: April 2023

Supplementary Data from OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Supplementary Figure 4 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

(A) Dot plot depicting expression levels of respective ligands and receptors together with the percentage of cells expressing them. (B) Top 10 percent of
interactions inferred between cell types in the TME. Edge weights are proportional to the number of interactions, circle sizes are proportional to the number of cells in each group, edge color represents the cell type as sender. For scale, autocrine interactions in CAFs are 68. (A-B)
Data from seven mCRCs and five paired normal liver tissue.
Supplemental Tables 1-8 from Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated SPP1+ Macrophages and Fibroblasts
Authors: Sathe Anuja , Mason Kaishu , Grimes Susan M. , Zhou Zilu , Lau Billy T. , Bai Xiangqi , Su Andrew , Tan Xiao , Lee HoJoon , Suarez Carlos J. , Nguyen Quan , Poultsides George , Zhang Nancy R. , Ji Hanlee P.
Published: April 2023

Supplemental Table 1: Antibodies, reporters, imaging order and exposure times used in CODEX imaging. EPCAM, SPP1, CD163 were excluded from downstream analysis due to non-specific staining; Supplemental Table 2: Sequencing metrics for scRNA-seq; Supplemental Table 3: Absolute number of cells detected from each sample per cell lineage; Supplemental Table 4: Differentially expressed genes belonging to respective macrophage clusters compared by site of sample origin. pct.1, pct.2 indicate percentage of cells expressing given gene in the cluster of interest and all other comparison clusters respectively; Supplemental Table 5: Enriched reactome pathways in differentially expressed genes in tumor macrophages; Supplemental Table 6: Gene signatures for Foam cells (Fernandez et.al., 2020, PMID 31591603) and scar-associated macrophages (Ramachandran et. al., 2020, PMID 31597160); Supplemental Table 7: Annotation of differentially expressed genes in CAFs with the components of the matrisome expression program; Supplemental Table 8: Spatial proximity analysis examining whether fibroblasts are more proximal to macrophages than any other cell type.
Supplementary Table S4 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Authors: Peng Ke , Zhang Feifei , Wang Yichen , Sahgal Pranshu , Li Tianxia , Zhou Jin , Liang Xiaoyan , Zhang Yanxi , Sethi Nilay , Liu Tianshu , Zhang Haisheng , Bass Adam J.
Published: April 2023

DigiWest Data
Figure S7 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Authors: Kang Kyung-Don , Bernstock Joshua D. , Totsch Stacie K. , Gary Sam E. , Rocco Abbey , Nan Li , Li Rong , Etminan Tina , Han Xiaosi , Beierle Elizabeth A. , Eisemann Tanja , Wechsler-Reya Robert J. , Bae Sejong , Whitley Richard , Gillespie G. Yancey , Markert James M. , Friedman Gregory K.
Published: April 2023

Interferon β (IFN β) levels over time in the CSF after a single 50 µg IVT dose of poly I:C or saline (N = 2 mice/group/time point).
Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Figure S3 shows a forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with distant recurrence free survival on the capecitabine arm vs. observation.
Supplementary Figure S1 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Latency of CCA_PDX generation. (A) The time from the implantation of CCA biopsies to the observation of the tumor growth in mice. The median [minimum – maximum] is indicated.
Supplementary Data from 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
Authors: Lee Yu-Jin , van den Berg Nynke S. , Duan Heying , Azevedo E. Carmen , Ferri Valentina , Hom Marisa , Raymundo Roan C. , Valencia Alex , Castillo Jessa , Shen Bin , Zhou Quan , Freeman Laura , Koran Mary Ellen , Kaplan Michael J. , Colevas A. Dimitrios , Baik Fred M. , Chin Frederick T. , Martin Brock A. , Iagaru Andrei , Rosenthal Eben L.
Published: April 2023

Supplementary Data from 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
Supplementary Figure S1 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Authors: Verhoeff Sarah R. , Oosting Sjoukje F. , Elias Sjoerd G. , van Es Suzanne C. , Gerritse Sophie L. , Angus Lindsay , Heskamp Sandra , Desar Ingrid M.E. , Menke-van der Houven van Oordt C. Willemien , van der Veldt Astrid A.M. , Arens Anne I.J. , Brouwers Adrienne H. , Eisses Bertha , Mulders Peter F.A. , Hoekstra Otto S. , Zwezerijnen Gerben J.C. , van der Graaf Winette T.A. , Aarntzen Erik H.J.G. , Oyen Wim J.G. , van Herpen Carla M.L.
Published: April 2023

Flow diagram of patient enrolment.
* Four patients were unfit for systemic treatment due to clinical deterioration resulting from rapid disease progression (n=3) or comorbidity and age (n=1). Three other patients did not wat systemic treatment.
Supplementary Data from A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Authors: Taniguchi Yuri , Shimokawa Tsuneo , Takiguchi Yuichi , Misumi Toshihiro , Nakamura Yukiko , Kawashima Yosuke , Furuya Naoki , Shiraishi Yoshimasa , Harada Toshiyuki , Tanaka Hisashi , Miura Satoru , Uchiyama Ayumi , Nakahara Yoshiro , Tokito Takaaki , Naoki Katsuhiko , Bessho Akihiro , Goto Yasuhiro , Seike Masahiro , Okamoto Hiroaki
Published: April 2023

Supplementary Data from A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Figure S2. Microbiome analysis in GBC.
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Authors: Shah Urvi A. , Maclachlan Kylee H. , Derkach Andriy , Salcedo Meghan , Barnett Kelly , Caple Julia , Blaslov Jenna , Tran Linh , Ciardiello Amanda , Burge Miranda , Shekarkhand Tala , Adintori Peter , Cross Justin , Pianko Matthew J. , Hosszu Kinga , McAvoy Devin , Mailankody Sham , Korde Neha , Hultcrantz Malin , Hassoun Hani , Tan Carlyn R. , Lu Sydney X. , Patel Dhwani , Diamond Benjamin , Shah Gunjan , Scordo Michael , Lahoud Oscar , Chung David J. , Landau Heather , Usmani Saad Z. , Giralt Sergio , Taur Ying , Landgren C. Ola , Block Gladys , Block Torin , Peled Jonathan U. , van den Brink Marcel R.M. , Lesokhin Alexander M.
Published: April 2023

Supplementary Table S1-S4
Supplementary Table 4 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

Characteristics of patients in non-randomized cohort who had <1cc of overlapped LBV and LADC MRI boostable tumor subvolume.
Supplementary Table 2 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

Patterns of Failure in all patients enrolled to clinical trial
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Authors: Kfir-Erenfeld Shlomit , Asherie Nathalie , Grisariu Sigal , Avni Batia , Zimran Eran , Assayag Miri , Sharon Tatyana Dubnikov , Pick Marjorie , Lebel Eyal , Shaulov Adir , Cohen Yael C. , Avivi Irit , Cohen Cyrille J. , Stepensky Polina , Gatt Moshe E.
Published: April 2023

Supplementary Data
Figure S2 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
Authors: Belhadj Sami , Khurram Aliya , Bandlamudi Chaitanya , Palou-Márquez Guillermo , Ravichandran Vignesh , Steinsnyder Zoe , Wildman Temima , Catchings Amanda , Kemel Yelena , Mukherjee Semanti , Fesko Benjamin , Arora Kanika , Mehine Miika , Dandiker Sita , Izhar Aalin , Petrini John , Domchek Susan , Nathanson Katherine L. , Brower Jamie , Couch Fergus , Stadler Zsofia , Robson Mark , Walsh Michael , Vijai Joseph , Berger Michael , Supek Fran , Karam Rachid , Topka Sabine , Offit Kenneth
Published: April 2023

Supplementary Figure S2. Rates of somatic loss of heterozygosity (LOH) in carriers of germline variants in the MRN complex genes as classified by A) PathoMAN and B) according to the variant type
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Authors: Ma Yuanqing , Joyce Allison , Brandenburg Olivia , Saatchi Faeze , Stevens Christina , Toffessi Tcheuyap Vanina , Christie Alana , Do Quyen N. , Fatunde Oluwatomilade , Macchiaroli Alyssa , Wong So C. , Woolford Layton , Yousuf Qurratulain , Miyata Jeffrey , Carrillo Deyssy , Onabolu Oreoluwa , McKenzie Tiffani , Mishra Akhilesh , Hardy Tanner , He Wei , Li Daniel , Ivanishev Alexander , Zhang Qing , Pedrosa Ivan , Kapur Payal , Schluep Thomas , Kanner Steven B. , Hamilton James , Brugarolas James
Published: April 2023

Figure S5
Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Authors: Ged Yasser , Sanchez Alejandro , Patil Sujata , Knezevic Andrea , Stein Emily , Petruzella Stacey , Weiss Kate , Duzgol Cihan , Chaim Joshua , Akin Oguz , Mourtzakis Marina , Paris Michael T. , Scott Jessica , Kuo Fengshen , Kotecha Ritesh , Hakimi A. Ari , Lee Chung-Han , Motzer Robert J. , Voss Martin H. , Furberg Helena
Published: April 2023

Table S6. Associations between SMI and length of prior treatment exposure before starting ICB among the 144 patients that received ICB in the second+ line setting
Table S7. The prevalence of SMI by the number of prior treatments received before starting ICB among the 144 patients that received ICB in the second+ line setting
Table S8. Characteristics of the TCGA cohort used for gene expression analysis by SMI
Supplementary Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Authors: Manning-Geist Beryl L. , Liu Ying L. , Devereaux Kelly A. , Paula Arnaud Da Cruz , Zhou Qin C. , Ma Weining , Selenica Pier , Ceyhan-Birsoy Ozge , Moukarzel Lea A. , Hoang Timothy , Gordhandas Sushmita , Rubinstein Maria M. , Friedman Claire F. , Aghajanian Carol , Abu-Rustum Nadeem R. , Stadler Zsofia K. , Reis-Filho Jorge S. , Iasonos Alexia , Zamarin Dmitriy , Ellenson Lora H. , Lakhman Yulia , Mandelker Diana L. , Weigelt Britta
Published: April 2023

Supplementary Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Authors: Quinn Zachary , Leiby Benjamin , Sonpavde Guru , Choudhury Atish D. , Sweeney Christopher , Einstein David , Szmulewitz Russell , Sartor Oliver , Knudsen Karen , Yang Eddy Shih-Hsin , Kelly Wm. Kevin
Published: April 2023

PSA waterfall plot
Figure S2 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Debie Yana , Van Audenaerde Jonas R.M. , Vandamme Timon , Croes Lieselot , Teuwen Laure-Anne , Verbruggen Lise , Vanhoutte Greetje , Marcq Elly , Verheggen Lisa , Le Blon Debbie , Peeters Bart , Goossens Maria E. , Pannus Pieter , Ariën Kevin K. , Anguille Sébastien , Janssens Annelies , Prenen Hans , Smits Evelien L.J. , Vulsteke Christof , Lion Eva , Peeters Marc , van Dam Peter A.
Published: April 2023

Supplementary Figure 2: Virus neutralization test with 50% neutralization titers (NT50) defined as the
sample dilution (reciprocal titer) conveying 50% neutralization in SARS-CoV-2 (strains 2019-nCoV-Italy-INMI1
and VLD20211207) infected wells.
Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in R/R T-ALL/LBL Patients with Donor-Derived CD7 CAR-T Therapy
Authors: Chen Wei , Shi Hui , Liu Zhuojun , Yang Fan , Liu Jia , Zhang Leqiang , Wu Yajin , Xia Yuanshi , Ou Yuxuan , Li Ruiting , Zhang Ting , Zhang Jiecheng , Ke Xiaoyan , Hu Kai , Yu Jian
Published: April 2023

Supplementary table 5
Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Patient disposition.
Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Any grade adverse event experienced in ≥2 patients.
Supplementary Table S4 from Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers
Authors: Cheema Amrita K. , Li Yaoxiang , Ventimiglia Mary , Kowalczyk Keith , Hankins Ryan , Bandi Gaurav , Janowski Einsley-Marie , Grindrod Scott , Villagra Alejandro , Dritschilo Anatoly
Published: April 2023

Test statistics comparing each post-RT time point to baseline (pre) in the GU cohort.
Supplementary Tables 1-5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Authors: Owen Dwight H. , Benner Brooke , Wei Lai , Sukrithan Vineeth , Goyal Ashima , Zhou Ye , Pilcher Carly , Suffren Sheryl-Ann , Christenson Gwen , Curtis Nancy , Jukich Megan , Schwarz Emily , Savardekar Himanshu , Norman Ruthann , Ferguson Sarah , Kleiber Barbara , Wesolowski Robert , Carson William E. , Otterson Gregory A. , Verschraegen Claire F. , Shah Manisha H. , Konda Bhavana
Published: April 2023

Supplementary Table 1: Most common treatment related adverse events; Supplementary Table 2: Treatment related serious adverse events; Supplementary Table 3: Mass Cytometry (CyTOF) panel; Supplementary Table 4: Mass cytometry gating of immune cell populations; Supplementary Table 5. Representativeness of Study Participants.
Supplementary Methods1 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Supplementary Methods
Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2023

DNA sequencing data summary.
Supplementary Table S1 from A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma
Authors: Ingham Matthew , Lee Shing , Van Tine Brian A. , Choy Edwin , Oza Jay , Doshi Sahil , Ge Liner , Oppelt Peter , Cote Gregory , Corgiat Brian , Sender Naomi , Sta Ana Sarah , Panchalingam Lavan , Petricoin Emmanuel , Schwartz Gary K.
Published: April 2023

Representativeness of Study Participants
Supplementary Table S2 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Essential scripts for each model and the specific parameters of the models.